Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | CTSA | P10619 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3820524 | 0.94 | ACHE (0.48) | ACHECTSAALOX15ALDH1A1L3MBTL1 | |
| SCHEMBL7546836 | 0.86 | ACHE (0.42) | ACHECTSAALOX15ALDH1A1L3MBTL1 | |
| SCHEMBL12503683 | 0.84 | ACHE (0.40) | ACHECTSAALOX15ALDH1A1L3MBTL1 | |
| SCHEMBL80155 | 0.83 | CTSA (0.56) | ACHECTSAALDH1A1L3MBTL1KDM4E | |
| SCHEMBL14748694 | 0.81 | ALOX15 (0.36) | ACHECTSAALOX15ALDH1A1LMNA | |
| SCHEMBL28848779 | 0.80 | TSHR (0.52) | ACHECTSAALDH1A1KDM4EPOLB | |
| SCHEMBL3628442 | 0.78 | CTSA (0.50) | ACHECTSAALDH1A1L3MBTL1KDM4E | |
| SCHEMBL23005635 | 0.77 | ALOX15 (0.34) | ACHECTSAALOX15ALDH1A1LMNA | |
| SCHEMBL14899309 | 0.77 | ALOX15 (0.34) | ACHECTSAALOX15ALDH1A1LMNA | |
| SCHEMBL28637397 | 0.77 | LMNA (0.36) | ACHECTSAALOX15ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023156652-A1 | ANTISENSE OLIGONUCLEOTIDE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-24 | — | — | WO | disclosed |
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-9540312-B2 | Non-flammable electrolyte composition including carbonate-terminated perfluoropolymer and phosphate-terminated or phosphonate-terminated perfluoropolymer and battery using same | Blue Current, Inc. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9543619-B2 | Functionalized phosphorus containing fluoropolymers and electrolyte compositions | Blue Current, Inc. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160226104-A1 | FUNCTIONALIZED PHOSPHORUS CONTAINING FLUOROPOLYMERS AND ELECTROLYTE COMPOSITIONS | Blue Current, Inc. | 2016-08-04 | — | — | US | disclosed |
| US-20160226103-A1 | FUNCTIONALIZED FLUOROPOLYMERS AND ELECTROLYTE COMPOSITIONS | Blue Current, Inc. | 2016-08-04 | — | — | US | disclosed |
| US-20160226102-A1 | FUNCTIONALIZED FLUOROPOLYMERS AND ELECTROLYTE COMPOSITIONS | Blue Current, Inc. | 2016-08-04 | — | — | US | disclosed |
| US-20160221926-A1 | FUNCTIONALIZED FLUOROPOLYMERS AND ELECTROLYTE COMPOSITIONS | Blue Current, Inc. | 2016-08-04 | — | — | US | disclosed |
| US-20160226101-A1 | FUNCTIONALIZED FLUOROPOLYMERS AND ELECTROLYTE COMPOSITIONS | Blue Current, Inc. | 2016-08-04 | — | — | US | disclosed |
| US-9296703-B2 | Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150368208-A1 | Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors | UNIVERSITY OF UTAH | 2015-12-24 | — | — | US | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221926-A1 | FUNCTIONALIZED FLUOROPOLYMERS AND ELECTROLYTE COMPOSITIONS | PEF1, PFAS, PFKFB3 | ACHE 4089/4885CTSA 3838/4885ALOX15 2853/4885 |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | ACHE 815/4885CTSA 1869/4885ALOX15 1133/4885 |
| US-20150368208-A1 | Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors | BTK, SYK, LYN | ACHE 3792/4885CTSA 3591/4885ALOX15 3551/4885 |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | ACHE 815/4885CTSA 1869/4885ALOX15 1133/4885 |
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | UGT2B7, UGT1A6, UGT1A1 | ACHE 1571/4885CTSA 3774/4885ALOX15 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.